Ankit Gupta has been appointed as Chief Executive Officer at Steriscience, alongside his role as Whole Time Director and CEO at InstaPill. In this expanded leadership capacity, he will spearhead next-generation dosage innovations, accelerate CDMO growth, and build globally scalable pharmaceutical solutions. His mandate focuses on advancing sterile injectables, strengthening patient-centric innovation, and positioning the organizations as high-value players in the global pharmaceutical ecosystem.

Ankit brings exemplary leadership experience across Gland Pharma Limited, Strides, Biocon, Cenexi, Christensen, Jay Switches India (P) Limited, and Parabolic Drugs. He has led strategic initiatives spanning mergers and acquisitions, investor relations, ESG frameworks, and large-scale business transformations. His expertise in global investments and post-merger integration has consistently delivered sustainable growth and operational excellence.

With a strong blend of financial acumen and strategic foresight, Ankit is well-positioned to drive long-term value creation and global competitiveness.

CXO TechBOT wishes Ankit Gupta great success in his new role.